Complement activation and coagulopathy - an ominous duo in COVID19.
Sojit TomoKiran Pvsn KumarDipayan RoyShrimanjunath SankanagoudarPurvi PurohitDharamveer YadavMithu BanerjeePraveen SharmaSanjeev MisraPublished in: Expert review of hematology (2021)
A tailored anticoagulant regimen, including intensification of standard prophylactic regimens with low-molecular-weight heparin is advisable for COVID-19 patients. Atypical manifestations and varying D-dimer levels seen in different populations bring forth the futility of uniform recommendations for anticoagulant therapy. Further, direct thrombin inhibitors and platelet inhibitors in a patient-specific manner should also be considered.